High CD133 Expression Is Associated with Worse Prognosis in Patients with Glioblastoma

Zhang, Wei; Chen, Huanran; Lv, Sheng‐Qing; Yang, Hui

doi:10.1007/s12035-015-9187-1

Cited by 25 publications

(20 citation statements)

References 44 publications

(95 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To determine the performance of this online tool, 53 previously published GBM prognostic factors collected as the procedure shown in Figure S1 and then they were evaluated in OSgbm (Table 2, Figure 1) (Sano et al, 1999;Hung and Howng, 2003;Heimberger et al, 2005;Aaberg-Jessen et al, 2009;Shirai et al, 2009;Pu et al, 2011;Cui et al, 2013;De Tayrac et al, 2013;Lee et al, 2013;Rosati et al, 2013;Wang et al, 2013;Wu et al, 2013;Bai et al, 2014;Han et al, 2014;Meng et al, 2014;Olmez et al, 2014;Zupancic et al, 2014;Maris et al, 2015;Moutal et al, 2015;Yan et al, 2015;Zhao et al, 2015;Chaurasia et al, 2016;Nduom et al, 2016;Steponaitis et al, 2016;Steponaitis et al, 2016;Zhang et al, 2016a;Zhang et al, 2016b;Deng et al, 2017;Dong et al, 2017;Ge et al, 2017;Han et al, 2017;Haynes et al, 2017;Huang et al, 2017;Li et al, 2017;Luo and Zhuang, 2017;Ma et al, 2017;Roy et al, 2017;Wu et al, 2017;Zhang et al, 2017;…”

Section: Validation Of Previously Reported Gbm Prognostic Biomarkersmentioning

confidence: 99%

OSgbm: An Online Consensus Survival Analysis Web Server for Glioblastoma

Dong

Wang

et al. 2020

Front. Genet.

View full text Add to dashboard Cite

Section: Validation Of Previously Reported Gbm Prognostic Biomarkersmentioning

confidence: 99%

OSgbm: An Online Consensus Survival Analysis Web Server for Glioblastoma

Dong

Wang

et al. 2020

Front. Genet.

View full text Add to dashboard Cite

“…However, given the limited therapeutic efficacy of TMZ, the importance of MGMT as a standard prognostic marker for GBM is compromised. There are microRNAs and some other genes such as epidermal growth factor receptor (EGFR) or CD133 that show a close correlation with GBM prognosis [ 13 – 17 ]. However, targeting them has not yet been very successful.…”

Section: Introductionmentioning

confidence: 99%

Survival kinase genes present prognostic significance in glioblastoma

et al. 2016

View full text Add to dashboard Cite

Cancer biomarkers with a strong predictive power for diagnosis/prognosis and a potential to be therapeutic targets have not yet been fully established. Here we employed a loss-of-function screen in glioblastoma (GBM), an infiltrative brain tumor with a dismal prognosis, and identified 20 survival kinase genes (SKGs). Survival analyses using The Cancer Genome Atlas (TCGA) datasets revealed that the expression of CDCP1, CDKL5, CSNK1E, IRAK3, LATS2, PRKAA1, STK3, TBRG4, and ULK4 stratified GBM prognosis with or without temozolomide (TMZ) treatment as a covariate. For the first time, we found that GBM patients with a high level of NEK9 and PIK3CB had a greater chance of having recurrent tumors. The expression of CDCP1, IGF2R, IRAK3, LATS2, PIK3CB, ULK4, or VRK1 in primary GBM tumors was associated with recurrence-related prognosis. Notably, the level of PIK3CB in recurrent tumors was much higher than that in newly diagnosed ones. Congruent with these results, genes in the PI3K/AKT pathway showed a significantly strong correlation with recurrence rate, further highlighting the pivotal role of PIK3CB in the disease progression. Importantly, 17 SKGs together presented a novel GBM prognostic signature. SKGs identified herein are associated with recurrence rate and present prognostic significance in GBM, thereby becoming attractive therapeutic targets.

show abstract

“…Thus, our data revel that CD133 is a key factor contributing to gallbladder carcinoma migration and invasion. Accumulated evidence from clinical and epidemiological studies has shown that high expression of CD133 is associated with poor prognosis in several different types, including brain tumours, colorectal carcinoma, rectal cancer, hepatoma, gastric carcinoma and medulloblastoma [ 27 – 30 ]. Our data also showed that the expression of CD133 was also significantly increased in gallbladder carcinoma as compared to normal tissues.…”

Section: Discussionmentioning

confidence: 99%

CD133 promotes gallbladder carcinoma cell migration through activating Akt phosphorylation

Yang

Zhen

et al. 2016

Oncotarget

View full text Add to dashboard Cite

Gallbladder carcinoma (GBC) is the fifth most common malignancy of gastrointestinal tract. The prognosis of gallbladder carcinoma is extremely terrible partially due to metastasis. However, the mechanisms underlying gallbladder carcinoma metastasis remain largely unknown. CD133 is a widely used cancer stem cell marker including in gallbladder carcinoma. Here, we found that CD133 was highly expressed in gallbladder carcinoma as compared to normal tissues. CD133 was located in the invasive areas in gallbladder carcinoma. Down-regulation expression of CD133 inhibited migration and invasion of gallbladder carcinoma cell without obviously reducing cell proliferation. Mechanism analysis revealed that down-regulation expression of CD133 inhibited Akt phosphorylation and increased PTEN protein level. The inhibitory effect of CD133 down-regulation on gallbladder carcinoma cell migration could be rescued by Akt activation. Consistent with this, addition of Akt inhibitor Wortmannin markedly inhibited the migration ability of CD133-overexpressing cells. Thus, down-regulation of CD133 inhibits migration of gallbladder carcinoma cells through reducing Akt phosphorylation. These findings explore the fundamental biological aspect of CD133 in gallbladder carcinoma progression, providing insights into gallbladder carcinoma cell migration.

show abstract

High CD133 Expression Is Associated with Worse Prognosis in Patients with Glioblastoma

Cited by 25 publications

References 44 publications

OSgbm: An Online Consensus Survival Analysis Web Server for Glioblastoma

OSgbm: An Online Consensus Survival Analysis Web Server for Glioblastoma

Survival kinase genes present prognostic significance in glioblastoma

CD133 promotes gallbladder carcinoma cell migration through activating Akt phosphorylation

Contact Info

Product

Resources

About